US Patent

US8722684 — 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment

Composition of Matter · Assigned to H Lundbeck AS · Expires 2031-06-30 · 5y remaining

Vulnerability score 15/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

The patent US 8722684 protects the compound 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine for its combined serotonin reuptake, 5-HT3, and 5-HT1A activity.

USPTO Abstract

1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT 3 and 5-HT 1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: US8722684
Jurisdiction: US
Classification: Composition of Matter
Expires: 2031-06-30
Drug substance claim: Yes
Drug product claim: Yes
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.